BIO VentureForum 2001 to Showcase 89 Leading Life Sciences Investment Opportunities

  • Contact: Ashley Myler, SheaHedges Group, (703) 287-7823
    Debbie Strickland, BIO, (202) 962-9200
  • Recommend
  • Tweet
  • Print
  • Email

Washington, D.C. (Sept. 17, 2001) - The Biotechnology Industry Organization (BIO), in partnership with the National Venture Capital Association, NASDAQ, the Technology Council of Maryland, and the Washington Business Journal, announced today the names of 89 biotechnology companies chosen for the first annual BIO VentureForum 2001. This select group of entrepreneurs will present their business plans to investors in an effort to secure first-, second- and third-round investments. The event will be held at the Hilton Washington & Towers on October 3-4, 2001, and is co-located with the seventh annual Maryland Bioscience Forum, sponsored by the Technology Council of Maryland's MD BioAlliance (www.mdhitech.org).

"BIO VentureForum's list of presenting companies is very impressive," said Michael Lytton, general partner at Oxford BioScience Partners and a member of the event's advisory board. "This is the only comprehensive conference that provides venture capitalists with direct access to the best entrepreneurial investment opportunities in life sciences."

Selected from across the United States, Europe and Asia, the presenting companies deliver cutting-edge therapies and technologies, including genomics, proteomics, chemistry and bioinformatics. California, Maryland and North Carolina are home to more than half of BIO VentureForum's participating businesses.

A complete list of presenting companies follows, and more information can be found at www.bioventureforum.net.

"Fueled by dynamic breakthroughs such as the mapping of the human genome, the biotechnology industry has established itself as a fast-growing market sector and has created remarkable opportunities for new drug discoveries and technologies," said BIO President Carl B. Feldbaum. "BIO VentureForum 2001 is an excellent platform for entrepreneurs to showcase promising new treatments to sophisticated investors and advance the product pipeline."

Scott Morrison, Ernst & Young's national director of life sciences, will address BIO VentureForum 2001 on Thursday, October 4, regarding "Focus on Fundamentals: The Biotechnology Report, Ernst & Young's 15th Annual Review."

Attendees will also be able to take advantage of the Technology Council of Maryland's BioScience Forum, co-located at the same venue. The forum will showcase Maryland universities and Maryland-based federal laboratories developing technologies available for commercialization through partnerships with established companies. A series of BioScience panel discussions will cover Bioinformatics/Computational Biology, Biocatalysis/Enzyme Research, Therapeutics, Agriculture/Environmental Applications, Medical Devices, and Diagnostics.

BIO VentureForum 2001 and Maryland BioScience Forum sponsors include Ernst & Young, LLP; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; FireRed.com; Friedman, Billings, Ramsey Group, Inc.; GATX Ventures, Inc.; Heller Ehrman White & McAuliffe LLP; Hogan & Hartson LLP; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC; Nomura International Plc; Reed Smith; Pacific Growth Equities, Inc.; Ropes & Gray; ShawPittman LLP; Silicon Valley Bank; Sun Microsystems; and UBS Warburg.

BIO VentureForum 2001 advisory board members include Academy Funds, Advent International Corporation, Alta Partners, Atlas Venture, Birchmere Ventures II LP, Burill & Company, Delphi Ventures, Dingman Center for Entrepreneurship, Domain Associates, Emerging Technology Partners, Intersouth Partners, InterWest Partners, Johnson & Johnson Development Corporation, Maryland Health Care Product Development Corporation, Mason Wells, MPM Capital Advisors LLC, National Capital Companies, Neuroventures Capital, NextGen Capital, Oxford BioScience Partners, Perseus-Soros Biopharmaceutical Fund, ProQuest Investments, Sofinnova Ventures Inc., S.R. One Ltd., Tenex Medical Investors, The Kaufmann Fund Inc., TVM Techno Venture Management, and Venrock Associates.

For more information on BIO VentureForum 2001, please visit the Web site at www.bioventureforum.net.

About BIO

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit www.bio.org .

BIO VentureForum 2001 Presenting Companies
20/20 Genesystems, Inc.
Achillion Pharmaceutics, Inc.

Addiction Therapies, Inc.

Advancis Pharmaceutical Corporation

Agensys, Inc.

Ancile Pharmaceuticals, Inc.

AngioGenex Inc.

AnVil Informatics, Inc.

Aptus Genomics, Inc.

Archemix Corporation

Artecel Sciences, Inc.

Athenix Solutions, Inc.

Automated Cell, Inc.

Auxilium A2, Inc.

Avantium Technologies B.V.

Big Bear Bio, Inc.

BioMat Sciences, Inc.

BioMicro Systems, Inc.

bioMosaic Systems, Inc.

Bionaut Pharmaceuticals, Inc.

BSI Proteomics Corporation

Cardio Vascular Genetic Engineering, Inc.

Clairus Technologies, Inc.

Claragen, Inc.

Cogent Neurosciences, Inc.

Copharos, Inc.

Corgentech Inc.

CropTech Corporation

CTIS, Inc.

Cytran, Inc.

Demegen Inc.

Diabetogen Biosciences Inc.

Dilon Technologies Inc.

Endeavor Pharmaceuticals, Inc.

EnVivo Pharmaceuticals, Inc.

FASgen, Inc.

First Genetic Trust, Inc.

Fluidigm Corporation

Functional Genetics Inc.

Gala Design, Inc.

Galileo Laboratories, Inc.

Gemin X Biotechnologies Inc.

Geneformatics Inc.

Genetix Pharmaceuticals, Inc.

Genteric, Inc.

Hemodyne, Inc.

ImPres Medical, Inc.

Ingenium Pharmaceuticals AG

Inhibitex Inc.

Intradigm Corporation

Iomai Corporation

Juvenir Biosciences Inc.

Libraria, Inc.

LifeTime Pharmaceuticals, Inc.

Locus Discovery, Inc.

Macrogenics, Inc.

Memory Pharmaceuticals, Inc.

Message Pharmaceuticals, Inc.

Metabolex, Inc.

MetriGenix, Inc.

MithraGen, Inc.

Mojave Therapeutics Inc.

NeuroMed Technologies Inc.

Neuronyx Inc.

Norak Biosciences Inc.

Novasite Pharmaceuticals

Odyssey Pharmaceuticals

Ontogen Corporation

Picoliter, Inc.

Plexxikon, Inc.

Pluvita Corporation

Psychiatric Genomics, Inc.

RenalTech International

Rheogene Inc.

Scimagix, Inc.

Sierra Sciences, Inc.

SLIL Biomedical Corp.

SomaLogic, Inc.

Spectral Genomics, Inc.

StemCo Biomedical, Inc.

Structural Bioinformatics, Inc.

SurfaceLogix, Inc.

Targacept, Inc.

TheraMed, Inc.

Valley Forge Pharmaceuticals, Inc.

Viral Genomix Inc.

Viron Therapeutics Inc.

Vizx Labs, LLC

YM Biosciences Inc.

# # #

For comments, or to subscribe/unsubscribe, please contact Carrie Housman at chousman@bio.org or call (202) 962-9200. Thank you.

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.